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Background: Some patients with systemic juvenile idio-
pathic arthritis (sJIA) experience a severe disease course
with destructive arthritis which is refractory to conventional
therapy including the “biologics,” and/or develop life
threatening complications such as macrophage activation
syndrome (MAS). This group of patients has been considered
for allogeneic hematopoietic stem cell transplantation
(HSCT). The aim of this study was to examine the outcome of
patients undergoing allogeneic HSCT for sJIA.
Methods: 8 patients (4 female) with sJIA underwent allo-
geneic HSCT at 3 UK transplant centers between 2007 and
2014. All patients were refractory to standard therapy (n¼4),
had failed autologous HSCT (n¼1), or developed secondary
HLH/MAS poorly responsive to treatment (n¼3). Median age
at transplant was 8.9 years (range 2 - 16 years). All received
reduced toxicity conditioning regimens: Fludarabine,
Melphalan, Alemtuzumab (n¼6) or Treosulfan, Fludarabine,Figure 1.Alemtuzumab (n¼2). All patients received peripheral blood
stem cell grafts: from a 10/10 HLA matched unrelated donor
(n¼5), 9/10 HLA mismatched unrelated donors (n¼2) and
matched sibling (n¼1). Patients received Cyclosporin (CsA)
and mycophenolate mofetil (MMF) for graft-vs-host disease
(GVHD) prophylaxis (n¼5), CsA alone (n¼2) and 1 patient
received Sirolimus and MMF due to previous CsA toxicity.
Results: Seven out of 8 patients are alive with median follow-
up of 16months (range 4 - 56months); one patient who had a
previous unsuccessful autologous HSCT died of severe meta-
bolic acidosis and hyperglycaemia following an orthopedic
procedure 20 months post successful mismatched unrelated
donorHSCT. Four patients achieved full donor chimerism in all
cell lineages and 4 (including both those who received Treo-
sulfan-based conditioning) achieved high levels of mixed
donor chimerism in all lineages. One patient had grade II and 1
patient had grade IV acute GVHD. With the use of Alemtu-
zumab in already heavily immunosuppressed patients, viral
reactivation was observed in most, some with a more severe
disease course (BK encephalitis; HHV6 enterocolitis). All pa-
tients had signiﬁcant improvement of arthritis (Fig 1),
reduction of ESR (Fig 2), resolution of MAS and improved
quality of life following allogeneic HSCT; all achieved
complete drug-free remission of JIA at last follow-up.
Conclusion: Allogeneic HSCT using Alemtuzumab and
reduced toxicity conditioning appears to be an effective
therapeutic option for patients with systemic onset JIAwhich
is refractory to conventional therapy and/or complicated by
MAS. Long term follow up is required to ascertain whether
disease control continues indeﬁnitely.26
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